Subacute sclerosing panencephalitis
Rare chronic, progressive encephalitis
| Subacute sclerosing panencephalitis | |
|---|---|
| [[File:|250px|alt=|]] | |
| Synonyms | SSPE |
| Pronounce | N/A |
| Field | Neurology |
| Symptoms | Behavioral changes, myoclonus, seizures, dementia |
| Complications | Death |
| Onset | 6-15 years after initial measles infection |
| Duration | Progressive |
| Types | N/A |
| Causes | Persistent measles virus infection |
| Risks | Measles infection at a young age |
| Diagnosis | EEG, MRI, CSF analysis |
| Differential diagnosis | Progressive multifocal leukoencephalopathy, Creutzfeldt-Jakob disease |
| Prevention | N/A |
| Treatment | Antiviral drugs, immunomodulatory therapy |
| Medication | N/A |
| Prognosis | Poor |
| Frequency | 1 in 100,000 measles infections |
| Deaths | N/A |
Subacute Sclerosing Panencephalitis (SSPE), also known as Dawson Disease, is a rare and devastating neurological disorder characterized by chronic progressive brain inflammation. This condition is caused by slow infection with certain defective strains of hypermutated measles virus. SSPE primarily affects children, teenagers, and young adults, with an estimated incidence of about 1 in 10,000 individuals who contract measles. In this comprehensive article, we will explore the definition, causes, clinical features, diagnosis, treatment, and implications of SSPE.
Understanding SSPE
Subacute Sclerosing Panencephalitis is a rare but severe complication of a prior measles infection. It is caused by the persistence of measles virus within the central nervous system.
Causes and Pathogenesis
The underlying cause of SSPE is believed to be the presence of defective and mutated measles virus particles within the brain. These altered viral particles can persist for years after the initial measles infection and gradually lead to neurological damage.
Signs and symptoms
SSPE is characterized by a history of primary measles infection, followed by an asymptomatic period that lasts 7 years on average but can range from 1 month to 27 years. After the asymptomatic period, progressive neurological deterioration occurs, characterized by behavior change, intellectual problems, myoclonic seizures, blindness, ataxia, and eventually death.[1][2]
Progression
Symptoms progress through the following 4 stages:[3]
- Stage 1: There may be personality changes, mood swings, or depression. Fever and headache may also be present. This stage may last up to 6 months.
- Stage 2: This stage may involve jerking, muscle spasms, seizures, loss of vision, and dementia.
- Stage 3: Jerking movements are replaced by writhing (twisting) movements and rigidity. At this stage complications may result in death.
- Stage 4: The final stage, in which breathing, heart rate, and blood pressure are affected, leading to coma and death.
Pathogenesis
A large number of nucleocapsids are produced in the neurons and the glial cells. In these cells the viral genes that encode envelope proteins have restricted expression.[4] As a result, infectious particles like the M protein are not produced, and the virus is able to survive persistently without evoking an immune response. Eventually the infection will lead to SSPE.[5]
Diagnosis
According to the Merck Manual:[2]
"SSPE is suspected in young patients with dementia and neuromuscular irritability. EEG, CT or MRI, CSF examination, and measles serologic testing are done. EEG shows periodic complexes with high-voltage diphasic waves occurring synchronously throughout the recording. CT or MRI may show cortical atrophy or white matter lesions. CSF examination usually reveals normal pressure, cell count, and total protein content; however, CSF globulin is almost always elevated, constituting up to 20 to 60% of CSF protein. Serum and CSF contain elevated levels of measles virus antibodies. Anti-measles IgG appears to increase as the disease progresses. If test results are inconclusive, brain biopsy may be needed."
Treatment
If the diagnosis is made during stage 1 it may be possible to treat the disease with oral isoprinosine (Inosiplex) and intraventricular interferon alfa, but the response to these drugs varies from patient to patient,[6] and the only accepted treatments are supportive measures such as anticonvulsants.[2]
Prognosis
In the classic presentation of the disease death occurs in 1 to 3 years,[7] but faster and slower progressions can occur. Faster deterioration in cases of acute fulminant SSPE leads to death within 3 months of diagnosis.[8][9]
Although the prognosis is bleak for SSPE past stage 1, there is a 5% spontaneous remission rate—this may be either a full remission that may last many years or an improvement in condition giving a longer progression period or at least a longer period with the less severe symptoms.[9][10]
Epidemiology
SSPE is a rare condition, although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine—eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself.
Epidemiology
SSPE is a rare condition, and its incidence varies by region and vaccination rates. In areas with high measles vaccination coverage, the occurrence of SSPE is significantly reduced.
Clinical Presentation
The clinical presentation of SSPE is characterized by progressive and debilitating neurological symptoms, including:
Cognitive Decline
Patients with SSPE often experience a decline in cognitive function, including memory loss, personality changes, and impaired intellectual abilities.
Muscle Spasticity
Muscle spasticity, characterized by muscle stiffness and involuntary contractions, is a common symptom of SSPE.
Seizures
Seizures are a frequent manifestation of SSPE and can vary in severity.
Visual Disturbances
Patients may experience visual disturbances, including blindness, due to damage to the optic nerve.
Diagnosis and Assessment
Diagnosing SSPE is based on a combination of clinical symptoms, medical history, and diagnostic tests, including cerebrospinal fluid analysis, electroencephalography (EEG), and neuroimaging.
Treatment and Management
There is no cure for SSPE, and treatment primarily focuses on symptom management and supportive care. Antiviral medications may be administered in an attempt to slow the progression of the disease, but their effectiveness is limited.
Prognosis and Implications
SSPE is a progressive and fatal disease, with a poor prognosis. The disease typically leads to severe disability and ultimately results in death. The course of the disease can vary, but it is universally devastating for affected individuals and their families.
Prevention
The most effective way to prevent SSPE is through measles vaccination. High vaccination rates contribute to herd immunity, reducing the incidence of measles and, consequently, SSPE.
| Infectious diseases – viral systemic diseases | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
 | |
|---|---|
 |
 |
- ↑ CDC pinkbook(link). {{{website}}}. 2019-03-29.
- ↑ 2.0 2.1 2.2 merckmanuals.com(link). {{{website}}}.
- ↑ medline.gov(link). {{{website}}}.
- ↑ , Jawetz. Melnick & Adelberg's Medical Microbiology, Lange, 2010, ISBN 978-0-07-174271-9, Pages: 586,
- ↑ , Defective translation of measles virus matrix protein in a subacute sclerosing panencephalitis cell line., Nature, 1983, Vol. 305(Issue: 5930), pp. 153–5, DOI: 10.1038/305153a0, PMID: 6888557, PMC: 7094927,
- ↑
- Gascon G, Yamanis S, Crowell J, et al. Combined oralisoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev. 1993; 15:346–55.
- Anlar B, Yalaz K, Oktem F,
- Cianchetti C, Marrosu MG, Muntoni F,
- ↑ SSPE information page www.ninds.nih.gov(link). {{{website}}}.
- ↑ Risk WS, Haddad FS, The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East, Arch Neurol, 1979, Vol. 56(Issue: 10), pp. 610–14, DOI: 10.1001/archneur.1979.00500460044004, PMID: 485888,
- ↑ 9.0 9.1 , Subacute sclerosing panencephalitis, Postgraduate Medical Journal, Vol. 78(Issue: 916), pp. 63–70, DOI: 10.1136/pmj.78.916.63, PMID: 11807185, PMC: 1742261,
- ↑
- Grunewald T, Lampe J, Weissbrich B,
- Santoshkumar B, Radhakrishnan K,
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
